The Effects of Endosomal Toll-like Receptor Inhibitors in an EBV DNA-Exacerbated Inflammatory Bowel Disease Mouse Model
Viruses · 2024
DOI: 10.3390/v16040624 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Iman Karout und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Pathology, Immunology, and Microbiology, American University of Beirut, Beirut 1107-2020, Lebanon. Hauptthemen laut MEDLINE: DNA, Viral, Herpesvirus 4, Human, Inflammatory Bowel Diseases, Toll-Like Receptors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American University of Beirut, Faculty of Medicine.
Abstract (Originalsprache)
Epstein–Barr virus (EBV), a Herpesviridae family member, is associated with an increased risk of autoimmune disease development in the host. We previously demonstrated that EBV DNA elevates levels of the pro-inflammatory cytokine IL-17A and that inhibiting Toll-like receptor (TLR) 3, 7, or 9 reduces its levels. Moreover, this DNA exacerbated colitis in a mouse model of inflammatory bowel disease (IBD). In the study at hand, we examined whether inhibition of TLR3, 7, or 9 alleviates this exacerbation. Mice were fed 1.5% dextran sulfate sodium (DSS) water and administered EBV DNA. Then, they were treated with a TLR3, 7, or 9 inhibitor or left untreated. We also assessed the additive impact of combined inhibition of all three receptors. Mice that received DSS, EBV DNA, and each inhibitor alone, or a combination of inhibitors, showed significant improvement. They also had a decrease in the numbers of the pathogenic colonic IL-17A+IFN-γ+ foci. Inhibition of all three endosomal TLR receptors offered no additive benefit over administering a single inhibitor. Therefore, inhibition of endosomal TLRs reduces EBV DNA exacerbation of mouse colitis, offering a potential approach for managing IBD patients infected with EBV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Pathology, Immunology, and Microbiology, American University of Beirut, Beirut 1107-2020, Lebanon.
- Department of Anatomy, Cell Biology and Physiological Sciences, American University of Beirut, Beirut 1107-2020, Lebanon.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL 32224, USA.
ORCID-Profile: Elio R Bitar, Omar Osman, Elias A Rahal
Förderung
- American University of Beirut, Faculty of Medicine
Zitieren
APA
Karout, I., Salhab, Z., Sherri, N., Bitar, E. R., Borghol, A. H., Sabra, H., Kassem, A., Osman, O., Alam, C., Znait, S., Assaf, R., Fadlallah, S., Jurjus, A., Hashash, J. G., & Rahal, E. A. (2024). The Effects of Endosomal Toll-like Receptor Inhibitors in an EBV DNA-Exacerbated Inflammatory Bowel Disease Mouse Model. Viruses. https://doi.org/10.3390/v16040624
Vancouver
Karout I, Salhab Z, Sherri N, Bitar ER, Borghol AH, Sabra H, et al. The Effects of Endosomal Toll-like Receptor Inhibitors in an EBV DNA-Exacerbated Inflammatory Bowel Disease Mouse Model. Viruses. 2024. doi:10.3390/v16040624
BibTeX
@article{Karout2024,
author = {Karout, Iman and Salhab, Zahraa and Sherri, Nour and Bitar, Elio R and Borghol, Abdul Hamid and Sabra, Hady and Kassem, Aya and Osman, Omar and Alam, Charbel and Znait, Sabah and Assaf, Rayan and Fadlallah, Sukayna and Jurjus, Abdo and Hashash, Jana G and Rahal, Elias A},
title = {The Effects of Endosomal Toll-like Receptor Inhibitors in an EBV DNA-Exacerbated Inflammatory Bowel Disease Mouse Model},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16040624}
}
EUVIMED